SCA
GILD icon

Strategic Capital Alternatives’s Gilead Sciences GILD Stock Holding History

Strategic Capital Alternatives’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$2.31M Sell
23,564
-16,232
-41% -$1.8M 0.49% 61
2015
Q2 		$4.13M Buy
39,796
+15,902
+67% +$1.74M 0.99% 28
2015
Q1 		$2.35M Buy
+23,894
New +$2.43M 0.58% 59
2014
Q4 		– Sell
-915
Closed -$97K – 186
2014
Q3 		$97K Buy
+915
New +$89.6K 0.03% 171

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Strategic Capital Alternatives's GILD Position: Q3 2015 in Review

Strategic Capital Alternatives reduced its Gilead Sciences (GILD) stake by 41% in Q3 2015, selling an estimated $1.8M and leaving 23,564 shares worth $2.31M. The position accounts for 0.49% of the portfolio, ranked #61.

Strategic Capital Alternatives first reported a position in GILD in Q3 2014 and has held it in 4 quarters since. The position peaked at $4.13M in Q2 2015. 1,575 funds tracked by Wall St. Rank hold GILD as of Q3 2015.

  • Strategic Capital Alternatives held 23,564 shares of Gilead Sciences worth $2.31M as of Q3 2015.
  • Strategic Capital Alternatives sold 16,232 Gilead Sciences shares in Q3 2015, an estimated $1.8M.
  • Gilead Sciences made up 0.49% of Strategic Capital Alternatives's portfolio in Q3 2015, its #61 holding.
  • Strategic Capital Alternatives first reported a position in Gilead Sciences in Q3 2014 and has held it in 4 quarters since.
  • Strategic Capital Alternatives's Gilead Sciences position peaked at $4.13M in Q2 2015.
  • 1,575 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.